[go: up one dir, main page]

WO2021136841A3 - Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires - Google Patents

Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires Download PDF

Info

Publication number
WO2021136841A3
WO2021136841A3 PCT/EP2020/088091 EP2020088091W WO2021136841A3 WO 2021136841 A3 WO2021136841 A3 WO 2021136841A3 EP 2020088091 W EP2020088091 W EP 2020088091W WO 2021136841 A3 WO2021136841 A3 WO 2021136841A3
Authority
WO
WIPO (PCT)
Prior art keywords
post
prevention
treatment
pharmaceutical composition
surgical pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/088091
Other languages
English (en)
Other versions
WO2021136841A2 (fr
Inventor
René AZOULAI
Xavier CASSARD
Jean-Pierre Salles
Jean-François ZAGURY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Original Assignee
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CNAM Conservatoire National des Arts et Metiers, Peptinov SAS filed Critical CNAM Conservatoire National des Arts et Metiers
Priority to US17/758,281 priority Critical patent/US20230293636A1/en
Priority to EP20845576.6A priority patent/EP4084818A2/fr
Priority to AU2020418554A priority patent/AU2020418554A1/en
Priority to JP2022540877A priority patent/JP2023508592A/ja
Priority to CA3163270A priority patent/CA3163270A1/fr
Publication of WO2021136841A2 publication Critical patent/WO2021136841A2/fr
Publication of WO2021136841A3 publication Critical patent/WO2021136841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent anti-IL-6 pour une utilisation dans une méthode de prévention ou de traitement de la douleur post-opératoire chez un individu.
PCT/EP2020/088091 2019-12-31 2020-12-31 Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires Ceased WO2021136841A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/758,281 US20230293636A1 (en) 2019-12-31 2020-12-31 Pharmaceutical composition for the prevention or treatment of post-surgical pain
EP20845576.6A EP4084818A2 (fr) 2019-12-31 2020-12-31 Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
AU2020418554A AU2020418554A1 (en) 2019-12-31 2020-12-31 Pharmaceutical composition for the prevention or treatment of post-surgical pain
JP2022540877A JP2023508592A (ja) 2019-12-31 2020-12-31 術後痛を予防又は治療するための医薬組成物
CA3163270A CA3163270A1 (fr) 2019-12-31 2020-12-31 Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306800 2019-12-31
EP19306800.4 2019-12-31

Publications (2)

Publication Number Publication Date
WO2021136841A2 WO2021136841A2 (fr) 2021-07-08
WO2021136841A3 true WO2021136841A3 (fr) 2021-09-02

Family

ID=69423052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/088091 Ceased WO2021136841A2 (fr) 2019-12-31 2020-12-31 Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires

Country Status (6)

Country Link
US (1) US20230293636A1 (fr)
EP (1) EP4084818A2 (fr)
JP (1) JP2023508592A (fr)
AU (1) AU2020418554A1 (fr)
CA (1) CA3163270A1 (fr)
WO (1) WO2021136841A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071706A1 (en) * 1998-03-17 2004-04-15 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agent for inflammatory bowel disease comprising IL-6 antagonist as an active ingredient
US20040121958A1 (en) * 1996-03-05 2004-06-24 The Regents Of The University Of California, A California Corporation Methods of alleviating neuropathic pain
US20090041717A1 (en) * 2007-08-10 2009-02-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2010088444A1 (fr) * 2009-01-29 2010-08-05 Medimmune, Llc Anticorps humains anti-il-6 à demi-vie prolongée in vivo et leur utilisation en oncologie et pour le traitement de maladies autoimmunes et inflammatoires
WO2013021284A2 (fr) * 2011-08-09 2013-02-14 Peptinov Sas Composition de vaccin anti-il-6
CN103421117B (zh) * 2012-05-16 2016-08-03 李岱宗 一种免疫增强型病毒样颗粒、其表达载体及其制备与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100252743B1 (ko) * 1994-12-29 2000-09-01 나가야마 오사무 Il-6 안타고니스트를 함유하는 항종양제의 작용증강제

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121958A1 (en) * 1996-03-05 2004-06-24 The Regents Of The University Of California, A California Corporation Methods of alleviating neuropathic pain
US20040071706A1 (en) * 1998-03-17 2004-04-15 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agent for inflammatory bowel disease comprising IL-6 antagonist as an active ingredient
US20090041717A1 (en) * 2007-08-10 2009-02-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2010088444A1 (fr) * 2009-01-29 2010-08-05 Medimmune, Llc Anticorps humains anti-il-6 à demi-vie prolongée in vivo et leur utilisation en oncologie et pour le traitement de maladies autoimmunes et inflammatoires
WO2013021284A2 (fr) * 2011-08-09 2013-02-14 Peptinov Sas Composition de vaccin anti-il-6
US20170333539A1 (en) * 2011-08-09 2017-11-23 Peptinov Sas Anti-il-6 vaccine composition
CN103421117B (zh) * 2012-05-16 2016-08-03 李岱宗 一种免疫增强型病毒样颗粒、其表达载体及其制备与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIPTI V TILLU ET AL: "Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain", MOLECULAR PAIN, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 23 January 2012 (2012-01-23), pages 5, XP021131587, ISSN: 1744-8069, DOI: 10.1186/1744-8069-8-5 *
LUCILLE DESALLAIS ET AL: "Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 16, no. 4, 24 July 2014 (2014-07-24), pages R157, XP021193638, ISSN: 1478-6354, DOI: 10.1186/AR4672 *
PASCALE VERGNE-SALLE: "Management of neuropathic pain after knee surgery", JOINT BONE SPINE, vol. 83, no. 6, 1 December 2016 (2016-12-01), AMSTERDAM, NL, pages 657 - 663, XP055677971, ISSN: 1297-319X, DOI: 10.1016/j.jbspin.2016.06.001 *
WANG S ET AL: "Expression of Central Glucocorticoid Receptors after Peripheral Nerve Injury Contributes to Neuropathic Pain Behaviors in Rats", THE JOURNAL OF NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, US, vol. 24, no. 39, 29 September 2004 (2004-09-29), pages 8595 - 8605, XP003003073, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.3058-04.2004 *

Also Published As

Publication number Publication date
CA3163270A1 (fr) 2021-07-08
US20230293636A1 (en) 2023-09-21
EP4084818A2 (fr) 2022-11-09
JP2023508592A (ja) 2023-03-02
AU2020418554A1 (en) 2022-08-25
WO2021136841A2 (fr) 2021-07-08

Similar Documents

Publication Publication Date Title
EP4349997A3 (fr) Anticorps anti-garp
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2018022668A3 (fr) Compositions neuromodulatrices et méthodes associées de traitement du cancer
MX2023002507A (es) Inhibidores de cd73.
ZA202204941B (en) Cd73 inhibitors
EP4445913A3 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie liée à c5 et procédé de traitement ou de prévention d'une maladie liée à c5
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
AU2017261286A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EP3821884A4 (fr) Utilisation d'un composé dans un médicament servant à prévenir, à traiter ou à soulager la douleur
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
HK1256174A1 (zh) 用於治疗疼痛的 vap-1 抑制剂
WO2021136841A3 (fr) Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
MY205171A (en) Methods of treatment of hypertriglyceridemia
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
CA3091759A1 (fr) Procedes et compositions pour maintenir l'efficacite des opioides dans le traitement de la douleur
WO2019115493A3 (fr) Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie
EP4234022A3 (fr) Bétahistine, ou un sel pharmaceutiquement acceptable de celle-ci, et un inhibiteur de monoamine oxydase, destinés à être utilisés dans le traitement ou la prévention d'un ou plusieurs symptômes de vertige chez un sujet
WO2017140684A3 (fr) Procédés et compositions pharmaceutiques pour le traitement d'un dysfonctionnement cognitif postopératoire
WO2020025657A9 (fr) Composition destinée à être utilisée dans la prévention et/ou le traitement de la muqueuse génito-urinaire
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
WO2019126695A3 (fr) Procédés et compositions pharmaceutiques pour traiter candida auris dans le sang

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20845576

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3163270

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022540877

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020845576

Country of ref document: EP

Effective date: 20220801

ENP Entry into the national phase

Ref document number: 2020418554

Country of ref document: AU

Date of ref document: 20201231

Kind code of ref document: A